Carlsmed, Inc. (NASDAQ:CARL) Given Average Rating of “Moderate Buy” by Analysts

Carlsmed, Inc. (NASDAQ:CARL) has earned an average rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $19.25.

Several analysts have recently weighed in on CARL shares. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Truist Financial increased their target price on shares of Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. BTIG Research restated a “buy” rating and issued a $23.00 price target on shares of Carlsmed in a report on Wednesday, May 6th. Needham & Company LLC assumed coverage on shares of Carlsmed in a research note on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price target for the company. Finally, Weiss Ratings upgraded shares of Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th.

Carlsmed Trading Up 3.5%

NASDAQ CARL opened at $16.75 on Friday. The business has a 50 day simple moving average of $12.70 and a 200 day simple moving average of $11.58. Carlsmed has a one year low of $8.50 and a one year high of $17.23. The stock has a market capitalization of $457.33 million and a P/E ratio of -11.71. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66.

Carlsmed (NASDAQ:CARL) last issued its earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $18.94 million during the quarter. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. Research analysts expect that Carlsmed will post -1.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Orbimed Advisors LLC acquired a new stake in Carlsmed in the third quarter valued at approximately $16,772,000. Jupiter Topco LLC bought a new stake in shares of Carlsmed during the second quarter valued at approximately $12,992,000. Parkman Healthcare Partners LLC acquired a new position in shares of Carlsmed during the second quarter worth approximately $6,200,000. BlackRock Inc. bought a new position in shares of Carlsmed in the 2nd quarter worth $5,528,000. Finally, Vanguard Group Inc. bought a new position in shares of Carlsmed in the 3rd quarter worth $3,042,000.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).